Royal Bank of Canada’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-38,000
Closed -$5.42M 7240
2024
Q2
$5.42M Buy
+38,000
New +$5.04M ﹤0.01% 2120
2023
Q3
Sell
-228,800
Closed -$18.5M 7413
2023
Q2
$18.5M Buy
+228,800
New +$18.7M ﹤0.01% 1208

Other funds holding NVO

Royal Bank of Canada's NVO Position: Q1 2026 in Review

Royal Bank of Canada increased its Novo Nordisk (NVO) stake by 3.2% in Q1 2026, buying an estimated $6.7M and bringing the position to 4,527,779 shares worth $166M. The position accounts for 0.03% of the portfolio, ranked #457.

Royal Bank of Canada first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $842M in Q2 2024. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Royal Bank of Canada held 4,527,779 shares of Novo Nordisk worth $166M as of Q1 2026.
  • Royal Bank of Canada bought 141,376 Novo Nordisk shares in Q1 2026, an estimated $6.7M.
  • Novo Nordisk made up 0.03% of Royal Bank of Canada's portfolio in Q1 2026, its #457 holding.
  • Royal Bank of Canada first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Novo Nordisk position peaked at $842M in Q2 2024.
  • 1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.